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To the Editor: Polymorphisms in adrenergic receptors are potential
risk factors for developing systolic heart failure (HF) presumably
via modulation of sympathetic nervous system activity (1). Two
such polymorphisms (2cDel322-325 and 1Arg389) appear to
have adverse synergistic effects, with the 2cDel322-325 receptor
increasing synaptic norepinephrine levels via loss of negative
feedback and the 1Arg389 receptor increasing responsiveness to
norepinephrine. In a prior study, others demonstrated that African
Americans with both of these polymorphisms were at increased
risk of HF (1). If this association was robust, we reasoned that
these 2 polymorphisms would also be strongly associated with
phenotypes that are precursors to systolic HF such as increased left
ventricular end-diastolic volume (EDV) and decreased left ven-
tricular ejection fraction (LVEF). The Dallas Heart Study (DHS),
a large multiethnic population-based probability sample of Dallas
County, afforded the opportunity to test this hypothesis.
The design of the DHS, conducted at 3 sequential visits, has
been described including sampling methods and validation (2),
assignment of race, and its cardiac magnetic resonance imaging
(MRI) and dual energy X-ray absorptiometry protocols (3,4). To
determine whether subjects had a history of HF, participants were
first asked: “Has a doctor or other health professional ever told you
that you had any kind of heart problems or a heart condition?” If
they answered “Yes,” they were subsequently asked: “Has a doctor
or other health professional ever told you that you have congestive
HF, an enlarged heart, a weak heart, or cardiomyopathy?” Subjects
who answered yes to both questions were classified as having a
history of HF. A reduced LVEF was defined as 61% in women
and 55% in men as recently reported (4). Gentoypes for
1Arg389 were ascertained using allelic discrimination (Applied
Biosystems, Foster City, California) and for 2cDel322-325 by a
size fractionation assay. For the latter, we amplified the ADRA2C
gene from genomic DNA using oligonucleotides 5=-FAM-
GTCTACGCGCGCATCTACCGAGTGGCCAAG-3=  anti-
sense primer 5=-CCCATGACCACAGCCAGCACAAAGGTG
AAG-3=. Amplicons were size-fractionated on an ABI 3100-
automated DNA sequencer. Informed consent was obtained, and
the Institutional Review Board of University of Texas Southwest-
ern Medical Center approved this protocol.
We restricted our analyses to participants who were white or
black, had available genotype data at the 2 loci of interest, and
underwent cardiac MRI (n  1,861). We classified subjects into 1
of 4 mutually exclusive categories (1): group 1: heterozygote or
wild-type at both loci; group 2: heterozygote or wild-type at
2cDel322-325 and homozygote at 1Arg389; group 3: homozy-
gote at 2cDel322-325 and heterozygote or wild-type at
1Arg389; and group 4: homozygote at both loci. Data were
analyzed using the SAS (version 9.1, SAS Corp., Cary, North
Carolina) statistical software package. Continuous variables are
presented as mean  SD. Associations between genotype and
categorical variables were tested using Fisher exact test. Group
differences in means of B-type natriuretic peptide were tested using
the non-parametric Kruskal-Wallis test. Group differences in
means of other continuous variables were tested using the 1-way
analysis of variance F-test of the group effect. Post hoc we
calculated the power to detect a 4-point LVEF difference and a 5
ml/m2 difference in EDV/body surface area (BSA) between groups
1 and 4 (see the preceding text). For all analyses, 2-tailed p values
0.05 were considered statistically significant.
Our study cohort included 1,121 African-American and 740
white subjects (58% and 51% women, respectively) with a mean
age of 45  10 years. The allele frequency of 2cDel322-325 was
0.40 in African Americans and 0.06 in whites, yielding 17% and
0.8% homozygous, respectively. The allele frequency of 1Arg389
was 0.58 in African-American and 0.72 in white subjects, yielding
35% and 52% homozygous, respectively. In African Americans,
the prevalence of diabetes was 13%, hypertension 42%, and obesity
(body mass index 30 kg/m2) 51%.
When African-American subjects were classified into 1 of 4
groups (1), we found no association between genotype group with
either B-type natriuretic peptide levels, self-reported history of
HF, or measures of left ventricular structure and function (Fig. 1).
When these analyses were repeated in white subjects, recognizing
the lower allele frequency of 2cDel322-325, there again was no
association of genotype group and cardiac traits (data not shown).
In African Americans, the power to detect a 4-point decrease in
LVEF in group 4 versus group 1 (from 74% to 70%) was 94%, and
the power to detect a 5-point increase in EDV/BSA between these
2 groups (from 51 to 56 ml/m2) was 81%.
In this study, we attempted to replicate the putative association
of 2cDel322-325 and 1Arg389 with increased risk of systolic
HF in African-American subjects (1). Although studies of white
Italian (5) and Japanese patients (6) have demonstrated no asso-
ciation of these polymorphisms and risk of HF, to our knowledge
no replication in African-American patients has been conducted.
We found very similar allele frequencies of 2cDel322-325 and
1Arg389 as previously reported (1). However, we were unable to
demonstrate an association of these 2 alleles with reduced LVEF
or increased ventricular volume, traits that are considered precur-
sors to systolic HF. Further, there was no association of genotype
with levels of B-type natriuretic peptide or self-reported history of
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HF. In total, these data question the strength of the association of
these alleles and risk of developing systolic HF.
The main limitation of our study is that the DHS is a healthier
population-based cohort as compared with the original study cohort
comprised of patients with symptomatic HF (1). Nevertheless, we had
94% power to detect an association of the polymorphisms with a
4-point decrement in LVEF and 81% power to detect an increase in
EDV/BSA of 5 ml/m2. Other polymorphisms in 2c-adrenergic
receptor have been shown to influence its expression, thereby poten-
tially modulating the cardiomyopathic properties of 2cDel322-325
(7). Although we did not genotype our subjects for these additional
polymorphisms and thus cannot perform a haplotype-based analysis,
it nevertheless was important to test the strength of the previously
reported association of 2cDel322-325 and 1Arg389 with risk of HF
in African-Americans subjects.
In a large population cohort of African-American subjects, we
found there was no association between the combination of
2cDel322-325 and 1Arg389 and traits commonly accepted to be
precursors of systolic HF.
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Letters to the Editor
Cost-Effectiveness of Upstream
Versus Selective Glycoprotein
IIb/IIIa Inhibitors for Acute
Coronary Syndromes
As a result of extensive clinical research during the past decades,
various treatment options are available today that might improve
the prognosis of patients with coronary disease. One of the
challenges for contemporary medicine is to implement these
therapies rationally in clinical practice, in the appropriate patients
at the appropriate time. In cost-conscious environments, treatment
decisions should not only be based on the suspected benefit/harm
ratio, but also on insights into therapy-related costs. Hence,
pharmaco-economical analyses are becoming increasingly impor-
tant in clinical cardiology.
In a recent issue of JACC, Glaser et al. (1) presented the results
of a pharmaco-economical analysis in patients presenting with
acute coronary syndromes (ACS) with moderate or high risk for
cardiovascular events. They concluded that the strategy of routine
upstream use of small-molecule (upstream-SM) glycoprotein (GP)
IIb/IIIa inhibitors is a more cost-effective approach than the
strategy of selective use of abciximab in patients who ultimately
undergo percutaneous coronary intervention (PCI).
Glaser et al. (1) performed a decision-tree analysis and used data
from clinical trials and a meta-analysis to define the probabilities on
the decision nodes. However, several discrepancies exist between the
applied probabilities and the data presented in the studies cited, most
of which favor the upstream-SM strategy. As an example, Glaser
assumes a relative risk (RR) in the range 0 (favoring upstream-SM) to
2.5 (favoring abciximab) for the incidence of death and myocardial
infarction (MI) in the PCI setting; yet according to the TARGET
(Do Tirofiban and ReoPro Give Similar Efficacy Outcomes?) trial, in
ACS patients the 95% confidence intervals (CIs) are 0.4 to 2.5 for
death and 1.1 to 2.0 forMI (2). Interestingly, the RR of 0 implies that
the upstream-SM strategy could produce survival for sure, which is
unrealistic. Glaser assumes a RR of 1.0 for major bleeding complica-
tions in patients undergoing PCI, whereas the TARGET trial reports
1.0% major bleeds after upstream-SM versus 0.7% after abciximab
(2). As a final example, Glaser et al. (1) assumes that the
upstream-SM strategy, as compared to control therapy, is associated
with a RR of 0.88 for death as well as for MI, with ranges varying
from 0.41 to 0.47 to 0.95. In fact, the meta-analysis of the corre-
sponding trials showed a 95% CI for the odds ratio of the composite
end point of 0.82 to 0.95 (3).
If all variations between the assumptions of Glaser et al. (1) and
the original studies are adjusted, results of the pharmaco-
economical analysis are reversed: the selective abciximab strategy is
then associated with a gain of 1,661 life-years per 100,000 patients,
and avoids 173 major bleeds, as compared to upstream-SM. Still,
this finding is unreliable. In fact, the presented decision-tree model
was insufficiently adjusted for uncertainty because the sensitivity
analysis that was applied did not alter all parameters at the same
time. Monte-Carlo simulation demonstrates a tremendous uncer-
tainty in any result of this study overall.
Decision-tree analyses might be useful to help clinicians make
rational, consistent, and cost-conscious decisions. However, given
the fact that average readers of clinical journals, including JACC,
are not specialists in medical decision making and pharmaco-
economics, authors of such analyses should be highly transparent
in their choices, and they should emphasize the uncertainties of
their conclusions. I am afraid that Glaser and colleagues missed
opportunities in this respect.
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